Trials / Completed
CompletedNCT00292435
Efficacy and Tolerability CVI (A 12-week, Double-blind, Randomised, Placebo-controlled, Multicentre Trial (CVI)
A 12-week, Double-blind, Randomised, Placebo-controlled, Multicentre Trial to Evaluate Efficacy and Tolerability of Antistax Film-coated Tablets, 360 mg/Day Orally, in Male and Female Patients Suffering From Chronic Venous Insufficiency.
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 202 (planned)
- Sponsor
- Boehringer Ingelheim · Industry
- Sex
- —
- Age
- —
- Healthy volunteers
- —
Summary
To determine efficacy and tolerability of Antistax 360 mg tablets in chronic venous insufficiency linked to edema (swelling) and subjective symptoms
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Read vine leaf extract (AS 195) |
Timeline
- Start date
- 2006-03-01
- Primary completion
- 2006-10-01
- First posted
- 2006-02-16
- Last updated
- 2013-10-29
Locations
16 sites across 3 countries: Austria, Czechia, Germany
Source: ClinicalTrials.gov record NCT00292435. Inclusion in this directory is not an endorsement.